Small PACS firms find survival difficultShakeout continues at a furious pace in the PACS and teleradiology markets, with Access Radiology and EMED apparently the latest firms to tie their futures together. As more of these small companies join
Shakeout continues at a furious pace in the PACS and teleradiology markets, with Access Radiology and EMED apparently the latest firms to tie their futures together. As more of these small companies join forces or are bought out by larger companies, power in the PACS industry is becoming concentrated in fewer and fewer hands.
While mergers and acquisitions provide a new lease on life for small companies and fill out product lines for larger firms, they also accentuate the tenuous existence of small firms and their difficulty in attracting customers.
Despite the hardships of the marketplace, smaller PACS firms have pioneered much of the leading-edge technology that is now standard issue for PACS companies. For example, the use of Windows NT and Web protocols, now employed by nearly all leading PACS firms, were trends begun by smaller firms.
Interest is growing in one-stop shopping for PACS and healthcare information systems, however, and there's no question that consolidation will continue in this sector. Smaller firms, particularly those selling directly to end users, will likely continue to struggle, with few exceptions.
All is not lost for small vendors, however. Innovative companies will continue to come into the market and generate useful PACS technology-but that technology will probably find its way to customers through OEM relationships rather than direct sales initiated by its developer. In the PACS market of the future, David and Goliath will find success through cooperation rather than confrontation.
-Erik L. Ridley, Editor
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.